Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, causing selective degradation of transcription factors such as Ikaros and Aiolos. This triggers enhanced activity of T‑cells and natural killer cells, suppresses angiogenesis, and directly induces apoptosis in malignant plasma cells and dysplastic hematopoietic progenitors, thereby exerting its antitumor effect.

The dose of Lenalidomid Zentiva is individualized by the treating physician based on the specific indication, disease stage, renal and hepatic function, and other patient‑specific factors. Prescribers determine the appropriate strength, frequency, and duration of therapy, and patients should follow the exact regimen provided in their prescription without deviation.

Lenalidomid Zentiva is classified as having an unknown pregnancy category, and animal studies suggest potential fetal risk. It is generally contraindicated in pregnant women, and effective contraception is required for both male and female patients of reproductive potential. Limited data exist for breastfeeding, so the drug should be avoided unless the benefits clearly outweigh the potential risks.

To request Lenalidomid Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent. Compared with thalidomide, lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy and constipation, while maintaining similar anti‑myeloma efficacy. Both drugs share mechanisms of immune modulation and anti‑angiogenesis, but lenalidomide’s enhanced potency and reduced toxicity make it a preferred option for many clinicians.

Lenalidomid Zentiva tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the product from excess moisture, direct sunlight, and extreme heat. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Lenalidomid Zentiva is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed. Patients should adhere to the dosing schedule and attend regular follow‑up appointments for laboratory monitoring.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia or thrombocytopenia that can predispose to infections and bleeding, and the possible development of secondary primary malignancies. Patients should promptly report symptoms like unexplained swelling, shortness of breath, fever, or unusual bruising to their healthcare provider.

Lenalidomid Zentiva should be avoided in patients who are pregnant, have known hypersensitivity to lenalidomide or any excipients, or have severe renal or hepatic impairment without appropriate monitoring. Additionally, individuals with a history of uncontrolled thromboembolic disease should not receive the drug unless anticoagulation is carefully managed under specialist supervision.